- Home
- DVAX vs QURE Comparison
DVAX vs QURE Comparison
Compare DVAX & QURE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DVAX | QURE |
|---|---|---|
| Founded | 1996 | 1998 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.9B |
| IPO Year | 2004 | 2007 |
Fundamental Metrics
Financial Performance| Metric | DVAX | QURE |
|---|---|---|
| Price | $15.50 | $25.59 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 13 |
| Target Price | $26.50 | ★ $56.25 |
| AVG Volume (30 Days) | ★ 2.6M | 2.1M |
| Earning Date | 02-20-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $330,514,000.00 | $15,751,000.00 |
| Revenue This Year | $24.63 | N/A |
| Revenue Next Year | $15.85 | $142.93 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 26.73 | N/A |
| 52 Week Low | $9.20 | $7.76 |
| 52 Week High | $15.73 | $71.50 |
Technical Indicators
Market Signals| Indicator | DVAX | QURE |
|---|---|---|
| Relative Strength Index (RSI) | 76.15 | 59.41 |
| Support Level | $15.46 | $24.37 |
| Resistance Level | $15.59 | $28.48 |
| Average True Range (ATR) | 0.06 | 1.93 |
| MACD | -0.16 | 0.54 |
| Stochastic Oscillator | 15.22 | 92.25 |
Price Performance
Historical ComparisonAbout DVAX Dynavax Technologies Corporation
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.
About QURE uniQure N.V.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.